Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 878 (115th)

Right to Try Act of 2017

referredUnited States· United States Congress· EN

Introduced

6 February 2017

Last action

2 March 2017 · Referred

Status

Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

Sponsors

Rep. Biggs, Andy [R-AZ-5], Rep. Fitzpatrick, Brian K. [R-PA-1], Sen. Cramer, Kevin [R-ND], Rep. Grothman, Glenn [R-WI-6], Rep. Messer, Luke [R-IN-6], Rep. Pittenger, Robert [R-NC-9], Rep. Stewart, Chris [R-UT-2], Rep. Lance, Leonard [R-NJ-7], Rep. Olson, Pete [R-TX-22], Rep. Franks, Trent [R-AZ-8], Rep. Lamborn, Doug [R-CO-5], Rep. Carson, André [D-IN-7], Sen. McSally, Martha [R-AZ], Rep. Yoho, Ted S. [R-FL-3], Rep. Rohrabacher, Dana [R-CA-48], Rep. Duncan, Jeff [R-SC-3], Rep. Lewis, Jason [R-MN-2], Rep. Barr, Andy [R-KY-6], Rep. Bridenstine, Jim [R-OK-1], Rep. Gohmert, Louie [R-TX-1], Sen. Banks, Jim [R-IN], Rep. Smucker, Lloyd [R-PA-11], Rep. Brat, Dave [R-VA-7], Rep. Sensenbrenner, F. James, Jr. [R-WI-5], Rep. Schweikert, David [R-AZ-1], Rep. Marino, Tom [R-PA-10], Rep. Rokita, Todd [R-IN-4], Rep. Issa, Darrell [R-CA-48], Rep. Griffith, H. Morgan [R-VA-9], Rep. Gaetz, Matt [R-FL-1], Rep. Hensarling, Jeb [R-TX-5], Rep. Bacon, Don [R-NE-2], Rep. Posey, Bill [R-FL-8], Rep. Abraham, Ralph Lee [R-LA-5], Sen. Sinema, Kyrsten [I-AZ], Rep. Graves, Tom [R-GA-14], Rep. Tipton, Scott R. [R-CO-3], Rep. Arrington, Jodey C. [R-TX-19], Rep. Correa, J. Luis [D-CA-46], Rep. Faso, John J. [R-NY-19], Rep. Polis, Jared [D-CO-2], Rep. Poe, Ted [R-TX-2], Rep. Hartzler, Vicky [R-MO-4], Rep. Comstock, Barbara [R-VA-10], Rep. Gosar, Paul A. [R-AZ-9], Rep. Meadows, Mark [R-NC-11], Rep. Brooks, Mo [R-AL-5], Rep. Rothfus, Keith J. [R-PA-12]

Subjects

Healthcare

Source updated

5 December 2025

Healthcare

Summary

Right to Try Act of 2017 This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are: (1) intended to treat a patient who has been diagnosed with a terminal illness, and (2) authorized by state law. The federal government must allow unrestricted possession and use of such treatments by patients certified by a physician as having exhausted all other treatment options. A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment. The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment. The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration; and (3) not be approved, licensed, or cleared for sale under the Federal Food, Drug, or Cosmetic Act or the Public Health Service Act.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 6 February 2017

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  2. 6 February 2017

    Introduced

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    Source: IntroReferral

  3. 6 February 2017

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 6 February 2017

    Introduced

    Introduced in House

    Source: IntroReferral

  5. 10 February 2017

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  6. 2 March 2017

    Referred

    Referred to the Subcommittee on the Constitution and Civil Justice.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 6 February 2017

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 6 February 2017

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 6 February 2017

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 92 sponsors and actors.

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.